duvelisib sold brand name copiktra medication used treat chronic lymphocytic leukemia cll small lymphocytic lymphoma sll follicular lymphoma treatments taken kinase common side effects include diarrhea low white blood cells rash feeling tired fever muscle serious side effects include inflammation lungs dual inhibitor duvelisib indicated treat adults chronic lymphocytic leukemia cll small lymphocytic lymphoma sll received least two prior therapies work stopped cll type cancer begins white blood cells sll type cancer begins mostly lymph duvelisib may cause infections diarrhea inflammation intestines lungs skin reactions high liver enzyme levels duvelisib may higher risk duvelisib phosphoinositide inhibitor specifically delta gamma isoforms class compounds works preventing playing role transducing signals outside cells various intracellular pathways involved cell cycle regulation apoptosis dna repair senescence angiogenesis cell metabolism including duvelisib also known discovered company founded september based biochemistry research lab kevan shokat university california san midjune infinity announced results phase ii clinical trial november infinity exclusively licensed worldwide rights duvelisib verastem oncology little money compared earlier deals deal included upfront payment million milestone success phase trial chronic lymphocytic leukemia million payment fda approval duvelisib received orphan drug designation united states treatment peripheral tcell lymphoma ptcl treatment chronic lymphocytic leukemia small lymphocytic lymphoma treatment follicular lymphoma september duvelisib sold verastem secura bio inc million additional payments based milestones us food drug administration fda required drug manufacturer secura bio submit final survival results clinical trial called duo trial phase iii randomized openlabel conducted participants cll sll received previous therapy work stopped final results showed possible increased risk death duvelisib compared monoclonal antibody rate serious side effects dose modifications deaths resulting side effects also higher among participants received serious side effects included infections diarrhea inflammation intestine lungs skin reactions elevated liver enzyme levels safety findings similar medicines kinase inhibitor april verastem filed new drug application nda duvelisib treatment relapsed refractory chronic lymphocytic leukemiasmall lymphocytic lymphoma cllsll accelerated approval relapsed refractory follicular lymphoma fl fda approved application september april fda withdrew approval duvelisib relapsed refractory follicular lymphoma request owner secura duvelisib intended used people received least two prior systemic therapies carries black box warning due risk fatalserious toxicities infections diarrhea colitis cutaneous reactions march committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product copiktra intended treatment adults relapsed refractory chronic lymphocytic leukaemia cll refractory follicular lymphoma applicant medicinal product verastem europe duvelisib approved medical use european union may httpsenwikipediaorgwikiduvelisib